RM-MET / Metabolic and incretin signalling
Exenatide
Also known as: Exendin-4 analog
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Exenatide is a synthetic version of exendin-4 and acts at the GLP-1 receptor. It is structurally different from human GLP-1 analogs and from long-acting Fc-fusion products.
Evidence position
FDA-labeled finished products and randomized human data support Grade A for the exact approved presentations.
What the record does not establish
The label and clinical literature do not verify the identity, concentration, sterility or stability of any other vial.
Sources
- 01Exenatide injection prescribing informationDailyMed / U.S. National Library of Medicine
- Shows
- U.S. finished-product label and initial approval history
- Does not show
- Does not describe a third-party research sample
- 02Effects of exenatide on glycemic control over 30 weeksPubMed
- Shows
- Randomized human trial of a defined exenatide presentation
- Does not show
- Clinical evidence is presentation-specific
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Exenatide
- CID
- 45588096
- Formula
- C184H282N50O60S
- Mass
- 4187
PUBMED / FOUND RECORDS
- Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.Diabetes care / 2018 FebPMID 29246950 / DOI 10.2337/dc17-0417
- Exenatide.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists / 2006 Mar 1PMID 16484515 / DOI 10.2146/ajhp050459
- Exenatide.Drugs of today (Barcelona, Spain : 1998) / 2005 SepPMID 16341288 / DOI 10.1358/dot.2005.41.9.893704
- Exenatide.Expert opinion on pharmacotherapy / 2007 OctPMID 17931093 / DOI 10.1517/14656566.8.15.2593
- Exenatide. / 2026 JanPMID 30085523
CLINICALTRIALS.GOV / FOUND RECORDS
- Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 DiabetesCOMPLETED / PHASE3 / AstraZenecaNCT01029886 / DIRECT intervention MATCH: Exenatide
- Incretin and KATP ChannelsTERMINATED / NA / Katarina KosNCT01934816 / DIRECT intervention MATCH: Exenatide
- The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant PatientsTERMINATED / PHASE3 / Universitätsklinikum Hamburg-EppendorfNCT03419624 / DIRECT intervention MATCH: Exenatide
- Brain Activation and Satiety in Children 2ACTIVE_NOT_RECRUITING / PHASE3 / Seattle Children's HospitalNCT04520490 / DIRECT intervention MATCH: Exenatide
- Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal SyndromeCOMPLETED / PHASE3 / Baylor Research InstituteNCT02251431 / DIRECT title MATCH: Exenatide